Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYW40T)

• Drug Name: (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate Drug Info
• Synonyms: (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid; (2R,4R)-APDC; (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid; 169209-63-6; 2R,4R-APDC; CHEMBL40086; CHEBI:40139; EN300-88063; 2R, 4R-APDC monohydrate; 52A; 4-amino-2,4-pyrrolidinedicarboxylic acid; AC1NSJRT; AC1Q4UAD; SCHEMBL158843; 2R, 4R-APDC; (2R,3R)-APDC; GTPL1392; CTK0E5090; DTXSID10415500; MolPort-003-982-102; BDBM50052398; ZINC32628523; SBB067830; MFCD16875409; AKOS015916056; AKOS015854214; RTC-065564; FCH3884669; NCGC00025040-02; LY314593; AJ-85443; SC-48823; TC-065564; B6634

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5310984
  ChEBI ID: CHEBI:40139
  CAS Number: CAS 169209-63-6
  TTD Drug ID: DMYW40T

Molecule-Related Drug Atlas

Drug(s) Targeting Metabotropic glutamate receptor 2 (mGluR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[2]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[3]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[4]
JNJ-64281802	DMNMSVX	Dengue	1D20-1D2Z	Phase 2	[5]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[6]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[7]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[8]
LY-2979165	DM16IX2	Bipolar disorder	6A60	Phase 1	[9]
JNJ-42491293	DMOL9JR	Psychiatric disorder	6E8Z	Phase 1	[10]
ADX71149	DMBUOX4	Epilepsy	8A60-8A68	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 2 (mGluR2)	TTXJ47W	GRM2_HUMAN	Agonist	[1]

References

• [1] Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci. 2002 Dec;116(6):1075-83.
• [2] Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
• [5] Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25.
• [6] Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
• [7] LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
• [8] Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
• [9] Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
• [10] Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708.
• [11] MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).